Metastases in the absence of a primary tumor: Advances in the diagnosis and treatment of CUP syndrome;Metastasen ohne primärtumor: Fortschritte in diagnostik und therapie des CUP-syndroms

Deutsches Arzteblatt

Volumn 105, Issue 43, 2008, Pages 733-740

  Neben, Kai ^a   Hübner, Gerdt ^b   Folprecht, Gunnar ^c   Jäger, Dirk ^d   Krämer, Alwin ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b SANA KLINIKUM OFFENBACH   (Germany)

^c DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^d Nationales Centrum fur Tumorerkrankungen   (Germany)

Author keywords

CUP syndrome; Diagnosis; Metastasis; Molecular medicine; Treatment success

Indexed keywords

ALPHA FETOPROTEIN; BEVACIZUMAB; BLEOMYCIN; CALCITONIN; CARBOPLATIN; CHORIONIC GONADOTROPIN BETA SUBUNIT; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; ERLOTINIB; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; IRINOTECAN; METHOTREXATE; MITOMYCIN C; NAVELBINE; PACLITAXEL; PROSTATE SPECIFIC ANTIGEN; VINBLASTINE;

CANCER OF UNKNOWN PRIMARY SITE; COMBINATION CHEMOTHERAPY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DNA MICROARRAY; DRUG TOLERABILITY; HUMAN; METASTASIS; MONOTHERAPY; REVIEW; STEM CELL TRANSPLANTATION; TUMOR BIOPSY;

EID: 56749177200     PISSN: 00121207     EISSN: None     Source Type: Journal    
DOI: 10.3238/arztebl.2008.0733     Document Type: Review

References (25)

1. Califano J, Westra WH, Koch W et al.: Unknown primary head and neck squamous cell carcinoma: molecular identification of the site of origin. J Natl Cancer Inst 1999; 91: 599-604.
2. Varadhachary GR, Abbruzzese JL, Lenzi R: Diagnostic strategies for unknown primary cancer. Cancer 2004; 100: 1776-85.
3. Abbruzzese JL, Abbruzzese MC, Lenzi R, Hess KR, Raber MN: Analysis of a diagnostic strategy for patients with suspected tumors of unknown origin. J Clin Oncol 1995; 13: 2094-103.
4. Greco FA, Burris HA, Litchy S et al.: Gemcitabine, carboplatin, and paclitaxel for patients with carcinoma of unknown primary site: a Minnie Pearl Cancer Research Network study. J Clin Oncol 2002; 20: 1651-6.
5. Culine S, Lortholary A, Voigt JJ et al.: Cisplatin in combination with either gemcitabine or irinotecan in carcinomas of unknown primary site: results of a randomized phase II study-trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAPI 01). J Clin Oncol 2003; 21: 3479-82.
6. Hübner G, Steinbach S, Kohne CH et al.: Paclitaxel/carboplatin versus gemcitabine/vinorelbine in patients with adeno- or undifferentiated carcinoma of unknown primary (CUP) - a randomized prospective phase-II-trial. Proc Am Soc Clin Oncol 2005; 23: 330 (Abstract 4089).
7. Palmeri S, Lorusso V, Palmeri L et al.: Cisplatin and gemcitabine with either vinorelbine or paclitaxel in the treatment of carcinomas of unknown primary site: results of an Italian multicenter, randomized, phase II study. Cancer 2006; 107: 2898-905.
8. Hess KR, Abbruzzese MC, Lenzi R, Raber MN, Abbruzzese JL: Classification and regression tree analysis of 1000 consecutive patients with unknown primary carcinoma. Clin Cancer Res 1999; 5: 3403-10.
9. Bugat R, Bataillard A, Lesimple T et al.: Summary of the standards, options and recommendations for the management of patients with carcinoma of unknown primary site (2002). Br J Cancer 2003; 89 (Suppl 1): 59-66.
10. Hainsworth JD, Spigel DR, Litchy S, Greco FA: Phase II trial of paclitaxel, carboplatin, and etoposide in advanced poorly differentiated neuroendocrine carcinoma: a Minnie Pearl Cancer Research Network Study. J Clin Oncol 2006; 24: 3548-54.
11. Kaufmann O, Fietze E, Dietel M: Immunohistochemical diagnosis in cancer metastasis of unknown primary tumor. Pathologie 2002; 23: 183-97.
12. Hossfeld DK, Wittekind C: Metastasen bei unbekanntem Primärtumor: Das CUP-Syndrom. Dtsch Arztebl 2005; 102 (13): A 904-7.
13. Sève P, Billotey C, Broussolle C, Dumontet C, Mackey JR: The role of 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography in disseminated carcinoma of unknown primary site. Cancer 2007; 109: 292-9.
14. Motzer RJ, Rodriguez E, Reuter VE, Bosl GJ, Mazumdar M, Chaganti RS: Molecular and cytogenetic studies in the diagnosis of patients with poorly differentiated carcinomas of unknown primary site. J Clin Oncol 1995; 13: 274-82.
15. Tothill RW, Kowalczyk A, Rischin D et al.: An expression-based site of origin diagnostic method designed for clinical application to cancer of unknown origin. Cancer Res 2005; 65: 4031-40.
16. Woods RL, Fox RM, Tattersall MH, Levi JA, Brodie GN: Metastatic adenocarcinomas of unknown primary site: a randomized study of two combination-chemotherapy regimens. N Engl J Med 1980; 303: 87-9.
17. Milliken ST, Tattersall MH, Woods RL et al.: Metastatic adenocarcinoma of unknown primary site: a randomized study of two combination chemotherapy regimens. Eur J Cancer Clin Oncol 1987; 23: 1645-8.
18. Eagan RT, Therneau TM, Rubin J, Long HJ, Schutt AJ: Lack of value for cisplatin added to mitomycin-doxorubicin combination chemotherapy for carcinoma of unknown primary site: a randomized trial. Am J Clin Oncol 1987; 10: 82-5.
19. Falkson CI, Cohen GL: Mitomycin C, epirubicin and cisplatin versus mitomycin C alone as therapy for carcinoma of unknown primary origin. Oncology 1998; 55: 116-21.
20. Assersohn L, Norman AR, Cunningham D et al.: A randomized study of protracted venous infusion of 5-fluorouracil (5- FU) with or without bolus mitomycin C (MMC) in patients with carcinoma of unknown primary. Eu J Cancer 2003; 39: 1121-8.
21. Dowell JE, Garrett AM, Shyr Y, Johnson DH, Hande KR: A randomized phase II trial in patients with carcinoma of an unknown primary site. Cancer 2001; 91: 592-7.
22. Briasoulis E, Kalofonos H, Bafaloukos D et al.: Carboplatin plus paclitaxel in unknown primary carcinoma: a phase II Hellenic Cooperative Oncology Group Study. J Clin Oncol 2000; 18: 3101-7.
23. Greco FA, Rodriguez GI, Shaffer DW et al.: Carcinoma of unknown primary site: sequential treatment with paclitaxel/carboplatin/etoposide and gemcitabine/irinotecan: a Minnie Pearl Cancer Research Network phase II trial. Oncologist 2004; 9: 644-52.
24. Massard C, Voigt JJ, Laplanche A et al.: Carcinoma of an unknown primary: are EGF receptor, Her-2/neu, and c-Kit tyrosine kinases potential targets for therapy? Br J Cancer 2007; 97: 857-61.
25. Hainsworth JD, Spigel DR, Farley C, Thompson DS, Shipley DL, Greco FA; Minnie Pearl Cancer Research Network: Phase II trial of bevacizumab and erlotinib in carcinomas of unknown primary site: the Minnie Pearl Cancer Research Network. J Clin Oncol 2007; 25: 1747-52.